Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147933 | 0.88 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL490615 | 0.88 | CHEK1 (0.58) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL490880 | 0.88 | CHEK1 (0.58) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL490678 | 0.87 | CHEK1 (0.57) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL490680 | 0.87 | CHEK1 (0.57) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL3605673 | 0.87 | CHEK1 (0.57) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL1148035 | 0.84 | CHEK1 (0.51) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL490943 | 0.84 | CHEK1 (0.51) | CHEK1IKBKBJAK2JAK3CDK2AP1 | |
| SCHEMBL1148112 | 0.83 | IKBKB (0.48) | CHEK1IKBKBJAK2JAK3MAP4K4 | |
| SCHEMBL1147574 | 0.83 | IKBKB (0.48) | CHEK1IKBKBJAK2JAK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297128-A1 | INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | claimed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | claimed |
| CN-102036979-A | IKK-beta serine threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2297128-A1 | INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2297128-A1 | INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CSNK1E, PACSIN2, CHUK | CHEK1 165/4885IKBKB 5/4885JAK2 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.